New hope for Hard-to-Treat myeloma: drug combo targets resistant cancer
Disease control
Ongoing
This early-phase trial tests a combination of three drugs (elotuzumab, mezigdomide, and dexamethasone) in 12 adults with multiple myeloma that has come back or stopped responding after prior treatments. The goal is to find the safest dose and see how well the body tolerates the r…
Phase: PHASE1 • Sponsor: Abdullah Khan • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC